ClinicalTrials.gg
RecruitingNCT05827848Updated Jun 28, 2024

Evaluate the Safety and Efficacy of a Peripheral Nerve Stimulation

An interventional study of Percutaneous peripheral nerve stimulation system in Complications; Prosthesis, Nervous System, Peripheral, Pain, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-28.

Primary conditionPainRegistry: Neurologic ManifestationsReclassifiedWhy we changed it
Registry
Neurologic Manifestations — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain
Why
  1. The study's listed conditions name Pain, a narrower term within Neurologic Manifestations.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.

Planned enrollment
152nd of 212
62 · median 120
Started
2022
with 16 others
No phase
117 of 247
40 open now
Primary completion
2024-12
later than 3 of 71 live
Registered
139th of 247
by date

Among the 247 studies in Pain with a site in China, this one is the 152nd largest by planned enrollment of the 212 interventional ones that give a count, is one of 17 that started in 2022, is one of 117 with no phase, reaches primary completion later than 3 of the 71 other live ones, and was the 139th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Pain with a site in China, or all of them as a file.
02

Study summary

This trial was conducted in a prospective, multicenter, randomized withdrawal design at a designated clinical trial facility. The total sample size for this trial is expected to be 59-62 patients.

One to two subjects were conducted in each study center as a preliminary test. A total of about 3-6 subjects were selected for the pre-test. The pre-test subjects used the test equipment (on state) and were not randomized.

The study was divided into screening/baseline period, treatment period (including test period, random withdrawal period and observation period) and follow-up period.

All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent Peripheral Nerve Stimulation(PNS) surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.

03

Conditions studied

  • Complications; Prosthesis, Nervous System, Peripheral, Pain

Browse trials for

Keywords

  • Peripheral nerve pain
04

In context

Pain Reclassified

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

This study's planned enrollment of 62 is close to the median of 66 across 8,512 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.

Compared within Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neurologic Manifestations. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old, gender unlimited;
  • The investigator judged that there was definite peripheral neuropathic pain (chronic and pain in the trunk and extremities, including chronic pain after sternal surgery; Postherpetic neuralgia), suitable for percutaneous peripheral nerve stimulation system treatment;
  • Preoperative assessment by neuropathic Pain Scale (DN4) showed that there were related damages or diseases in the peripheral sensory system;
  • Patients with poor efficacy or can not tolerate the side effects of treatment after routine treatment;
  • Visual analogue scale (VAS)≥50mm within 24 hours before treatment;
  • The subject can understand the study purpose, demonstrate sufficient compliance with the study protocol, and be able and willing to sign the .

Exclusion criteria

Exclusion Criteria:

  • Patients who need to be treated with radiofrequency regulation and intrathecal drug infusion;
  • Patients who are known to have had heart implants (pacemakers or defibrillators) or other implanted neurostimulators (spinal cord stimulators or deep brain stimulators, etc.);
  • Patients with severe psychological and/or psychiatric illness and/or non-therapeutic drug dependence;
  • Patients who are expected to undergo MRI within 30 days after PNS implantation;
  • Expected to be discharged within 48 hours or less;
  • There is known damage to the target nerve or muscle defect in the pain area;
  • Patients with known allergies to skin-to-skin contact materials (tape or adhesive);
  • Known allergy to anesthetics such as lidocaine;
  • Preoperative complications of severe heart, liver, kidney, respiratory diseases and coagulopathy;
  • Pregnant or lactating women, or have a birth plan in the next 3 months;
  • Is participating in any other drug or medical device clinical trial, or may participate in any other drug or medical device clinical trial after enrollment in this clinical trial;
  • The investigator determined that there were other conditions that were not suitable to participate in the clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Turn on the machine for continuous nerve stimulation

    Device: Percutaneous peripheral nerve stimulation system

  • No intervention
    control group

    Turn off the machine

Interventions

  • DevicePercutaneous peripheral nerve stimulation system

    All subjects underwent a 7-day baseline assessment (VAS score for at least 4 days) during the screening/baseline period. Eligible subjects underwent PNS surgery and implanted electrode leads and entered the 7-day test period. During the test period, subjects with an average VAS score improvement of ≥30%(VAS score for at least 4 days) will be randomly assigned to the experimental group (on state) or the control group (off state) in a 1:1 ratio for 7 days observation. All subjects were enrolled in the observation period until 28 days after implantation. Safety assessment was performed at a 14-day follow-up after removal of the device.

07

What researchers measure

Primary outcomes

  1. Difference of the mean VAS scores of the experimental group and the control group during the random withdrawal period

    (VASEGbase -- VASEGwd) Average - (VASCGbase -- VASCGwd) Average Explanation: VASEGbase was the mean VAS score of subjects in the experimental group at 4 days before the random withdrawal period. VASEGwd was the maximum VAS score of subjects in the experimental group during the random withdrawal period. VASCGbase was the mean VAS score of subjects in the control group at 4 days before the random withdrawal period. The maximum VAS score of subjects in the VASCGwd control group during the random withdrawal period.

    Time frame: 7 days after the wire implantation test period

08

Study locations

1 of 1 sites recruiting
  • Ke Ma, PhD
    Shanghai, Shanghai 200000, China
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 25 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Apr 25, 2023
StartActual
Oct 28, 2022
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05827848
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Oct 28, 2022
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Jun 28, 2024

Study contacts

Ke Ma, PhD
Contact
marke72@163.com
86-21-25078707

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion